Preclinical study demonstrates enhanced motor neuron protection via autocrine IGF-I expression in human spinal stem cells, suggesting an additive strategy for ALS cellular therapy.
Key Points
To determine whether autocrine production of insulin-like growth factor-I (IGF-I) enhances the neuroprotective capacity and biological performance of human spinal stem cells in ALS models.
Engineered human spinal stem cells (HSSCs) to express sixfold higher levels of IGF-I and evaluated their proliferation, terminal differentiation, and neurite outgrowth in vitro.
Quantified the secretion of downstream neuroprotective factors, specifically glial-derived neurotrophic factor (GDNF).
Tested neuroprotection against excitotoxic injury using primary motor neuron co-cultures with hanging inserts (indirect) and organotypic spinal cord slice cultures (direct).
IGF-I-overexpressing HSSCs accelerated neurite outgrowth and elevated GDNF production without compromising normal stem cell proliferation or differentiation.
Elevated autocrine IGF-I significantly increased motor neuron survival against excitotoxicity through both direct tissue contact and indirect paracrine mechanisms.